Pharmaceuticals & Therapeutics

With a major new facility planned and a dynamic market, all eyes are on Clean Harbors as it prepares to address investors at two key January events.

With major clinical trials, including a novel approach for Alzheimer's, and key market access wins, MMI's Symani system is poised to redefine microsurgery.

With enrollment complete for three major trials, MediciNova braces for a transformative year with crucial data expected for its ALS and metabolic disease candidates.

A new philanthropic fund, Lupus Ventures, aims to end treatment stagnation by investing directly in the most promising biotech innovations for lupus.

Newcomer Candid Therapeutics is set to unveil its T-cell engager platform at J.P. Morgan, a move that could shake up the autoimmune treatment landscape.

In a strategic move to become a one-stop shop for medical implants, Resonetics acquires pulse generator tech, targeting the booming neuromodulation and BCI markets.

Health Canada greenlights an 8-week pill for acute HCV, a move experts say is a game-changer in the race to eradicate the virus by 2030.

Weight-loss drugs offer powerful results, but what happens next? New programs aim to build lasting habits, addressing the missing link for long-term success.

Processa Pharmaceuticals completes enrollment for a pivotal analysis of its NGC-Cap therapy, offering new hope for a safer, more effective cancer treatment.

BridGene Biosciences adds Nobel winner Dr. Bruce Beutler to its board, gaining immense credibility for its mission to create drugs for intractable diseases.

With a hot obesity pipeline and a key neurology asset, Nxera Pharma's J.P. Morgan talk is a crucial test of its plan for global leadership.

With a $257M war chest and a veteran team, BlossomHill will showcase its innovative pipeline for lung cancer and leukemia at the pivotal JPM conference.

With surging revenue for its cholesterol drugs and new guideline backing, Esperion outlines its strategy for profitability and pipeline expansion.

With a key presentation looming, Star Therapeutics aims to showcase its universal hemostatic therapy, VGA039, for von Willebrand disease.

South Korea's Curogen secures major national funding and targets global partners at the JP Morgan conference, advancing novel therapies for IBD and HS.

A global RFA leader unveils a new identity, reflecting a strategic shift from pure engineering to a focus on the patient's quality of life.

Tango Therapeutics adds seasoned CFO Sung Lee to its board, a strategic move to guide its lead cancer drug, vopimetostat, through late-stage trials.

Sanofi is investing up to $2.56 billion in Earendil Labs' AI platform to discover next-gen bispecific antibodies for complex autoimmune diseases.

Health Canada has approved JERAYGO, the first new hypertension drug class in 30 years, offering a lifeline to patients with hard-to-treat high blood pressure.

The eye health giant has refinanced a massive $2.8B in loans, extending debt maturity and cutting interest costs to bolster its long-term strategy.